The company’s PLacental eXpanded cells have potential as a cell therapy product for muscle and tendon regeneration that can be used to enhance repair after rotator cuff surgery.
There are currently no U.S. Food and Drug Administration-approved therapies using engineered cells for rotator cuff injuries.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
